Biblioteca Virtual em Saúde

Pesquisa | Influenza A (H1N1)

  • BIREME | OPAS | OMS logo

ECDC TECHNICAL DOCUMENT: Protocol for case-control studies to measure influenza vaccine effectiveness in the European Union and European Economic Area Member States

Autor(es): The European Centre for Disease Prevention and Control
Fonte: Stockholm; ECDC; July. 2009. 25 p.
Repositório Complementar ID: 238
Resumo: The recent occurrence of the new A(H1N1)v virus augments the importance of obtaining reliable and early vaccine effectiveness estimates for the pandemic vaccine. VE studies are needed to determine the effectiveness of the new vaccine once it is made available. In addition, VE studies may help determining if the seasonal influenzavaccination is effective in protecting against the A(H1N1)v virus. Currently, only observational studies can be used to provide real-time estimates of influenza VE in Europe. In order to estimate real-time influenza VE, it is necessary to define which methods can be adopted in the European Union and the European Economic Area (EU/EEA) Member States. These methods have to take into account the specific situation of each Member State in terms of resources and available data. It is assumed that expertise developed during seasonal influenza season can be applied when measuring influenza VE during a pandemic. During the 2008-09 influenza season, the European Centre for Disease Prevention and Control (ECDC) funded fivepilot cohort studies (Portugal, Spain, Denmark, Romania, Hungary) to measure influenza vaccine effectiveness in the elderly (>= 60 or >= 65 years old). The five pilot studies were based on GP surveillance networks. Four of them used the influenza-like illness (ILI) EU case definition. All of them included a common set of variables toadjust for positive and negative confounding.